businesspress24.com - Prism Medical Ltd. Stock Option Amendments
 

Prism Medical Ltd. Stock Option Amendments

ID: 1253005

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 08/08/13 -- Prism Medical Ltd. ("Prism Medical" or the "Company") (TSX VENTURE: PM), a leading provider of durable medical equipment and related services to the mobility challenged, announced today that it has been granted conditional approval from the TSX Venture Exchange Inc. to amend certain stock option agreements affecting options to acquire 247,000 common shares at prices ranging from $4.72 to $5.20, by extending the expiry dates to May 31, 2014. The reason for the amendment is that the Company's stock option plan does not allow for automatic extensions of the "expiry date" of options if the expiry date occurs during a "blackout" period pursuant to the Company's securities trading policy. As a result the optionees may not be able to exercise outstanding options. The Company intends to present an amendment to the stock option plan addressing this issue for approval by the shareholders at the next annual meeting to be held prior to the end of May, 2014.

About Prism Medical Ltd.

Prism Medical Ltd. is one of the largest providers and manufacturers of durable medical equipment and related services to the mobility challenged in Canada, the US and the UK, with more than 100,000 installations and 200,000 product solutions sold. The Prism Medical brands include Waverley Glen and ErgoSafe, North America's leading supplier of lifting, handling and repositioning aid products and services across Canada and the US. Freeway and Prism Service & Repair are leading suppliers of moving and handling products and services in the UK. For further information visit Prism Medical's website at or .

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.



Contacts:
Prism Medical Ltd.
George Chiarucci
Chief Financial Officer
416-260-2145 ext. 229




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Insulet Reports Second Quarter 2013 Results
Rosetta Genomics and Ramot at Tel Aviv University Awarded Grant From Israeli Office of the Chief Scientist to Support Development of microRNA Oncology Therapeutics
Bereitgestellt von Benutzer: Marketwired
Datum: 08.08.2013 - 07:01 Uhr
Sprache: Deutsch
News-ID 1253005
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Medical Devices


Anmerkungen:


Diese Pressemitteilung wurde bisher 150 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Prism Medical Ltd. Stock Option Amendments
"
steht unter der journalistisch-redaktionellen Verantwortung von

Prism Medical Ltd. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Prism Medical Ltd.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 68


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.